CStone Pharmaceuticals
CStone Pharmaceuticals, a biopharmaceutical company, researches and develops anti-cancer therapies to address the unmet medical needs of cancer patients in Mainland China and internationally. The company offers CEJEMLY (sugemalimab), a monoclonal antibody against programmed death (PD) ligand 1 for the treatment of non-small cell lung cancer (NSCLC), gastric adenocarcinoma/gastroesophageal junctio… Read more
CStone Pharmaceuticals (CSPHF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.429x
Based on the latest financial reports, CStone Pharmaceuticals (CSPHF) has a cash flow conversion efficiency ratio of -0.429x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-156.05 Million) by net assets ($363.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CStone Pharmaceuticals - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how CStone Pharmaceuticals's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
CStone Pharmaceuticals Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CStone Pharmaceuticals ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Yangdian Science & Technology Co. Ltd.
SHE:301012
|
0.114x |
|
Gravita India Limited
NSE:GRAVITA
|
-0.022x |
|
Canada Goose Holdings Inc
NYSE:GOOS
|
-0.226x |
|
SunOpta Inc.
NASDAQ:STKL
|
0.092x |
|
Boss Resources Ltd
OTCQX:BQSSF
|
-0.002x |
|
V V Food & Beverage Co Ltd
SHG:600300
|
0.083x |
|
Lake Materials Co. Ltd.
KQ:281740
|
0.072x |
|
Aavas Financiers Limited
NSE:AAVAS
|
-0.027x |
Annual Cash Flow Conversion Efficiency for CStone Pharmaceuticals (2016–2024)
The table below shows the annual cash flow conversion efficiency of CStone Pharmaceuticals from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $363.87 Million | $-343.18 Million | -0.943x | +26.83% |
| 2023-12-31 | $456.83 Million | $-588.84 Million | -1.289x | +5.44% |
| 2022-12-31 | $449.33 Million | $-612.47 Million | -1.363x | -10.86% |
| 2021-12-31 | $1.21 Billion | $-1.48 Billion | -1.230x | -614.97% |
| 2020-12-31 | $2.95 Billion | $-508.07 Million | -0.172x | +60.51% |
| 2019-12-31 | $2.48 Billion | $-1.08 Billion | -0.435x | +71.63% |
| 2018-12-31 | $515.33 Million | $-791.11 Million | -1.535x | -188.29% |
| 2017-12-31 | $451.05 Million | $-240.19 Million | -0.533x | -91.73% |
| 2016-12-31 | $766.96 Million | $-213.01 Million | -0.278x | -- |